搜索
Search
img

ABOUT US

关于开拓

About Suzhou Kintor

Company Profile

  • Categories:关于我们
  • Time of issue:2019-04-14 00:00:00
  • Views:0
Description:
Description:
Information

Founded in 2009, Kintor Pharmaceuticals focuses on developing innovative small molecules and biologic drugs for androgen-related diseases with significant unmet needs, including treatments for, COVID-19 prostate cancer, breast cancer, liver cancer, alopecia, acne, and other conditions.

 

On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.

 

Kintor Pharmaceuticals’ product pipeline includes innovative small molecule drugs, biologics, and combination therapies. The product pipeline consists of six products undergoing clinical research, including androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR inhibitors, Hedgehog/SMO inhibitors, and an AR-PROTAC. The company also has ongoing preclinical programs in PD-L1/TGF-β dual-targeting antibody and c - Myc inhibitors.

 

Kintor Pharmaceutical has been granted more than 60 patents worldwide. Many of the company’s projects were listed as National Special Projects for Significant Novel Drugs Development during the 12th (2011-2015) and 13th (2016-2020) Five-Year Plans.

 

Kintor Pharmaceutical’s lead product, proxalutamide, is undergoing clinical trials in China and the United States for the treatment of COVID-19 infection, Metastatic Castration-Resistant Prostate Cancer (mCRPC) and metastatic breast cancer.

 

In August 2020, Kintor announced that the capitalization of its Suzhou Industrial Park research and development (R&D) center and manufacturing facility. The facility covers some 20,000 square meters. Designed to meet all of Kintor’s manufacturing needs, the facility was designed and constructed using state-of-the-art technologies and complies with international good manufacturing practices (GMP) standards.

 

Kintor’s management team has extensive experience in the research and development of novel drugs and the management of start-up pharmaceutical companies. Under their leadership, the company has attracted a group of outstanding domestic and foreign professionals experienced with managing all aspects of drug development and leading multinational pharmaceutical companies.

Scan the QR code to read on your phone